Allyx Therapeutics Announces First Parkinson’s Disease Patient Treated with ALX-001
04. September 2024 08:00 ET
|
Allyx Therapeutics Inc.
Allyx Therapeutics first patient first patient has been dosed with its lead compound, ALX-001, in new Parkinson's Disease clinical study
RaceTrac Adds Java Jolt to Parkinson’s Research Funding and Awareness with 13th Annual ‘Coffee For A Cause’ Week
27. März 2024 13:31 ET
|
Racetrac, Inc.
Atlanta, March 27, 2024 (GLOBE NEWSWIRE) -- In recognition of Parkinson’s Awareness Month, RaceTrac is once again proud to partner with The Michael J. Fox Foundation (MJFF) by offering ‘Coffee For A...
Allyx Therapeutics Announces Positive Phase 1b Multiple Ascending Dose Data and Advances ALX-001 to Patients
11. März 2024 08:05 ET
|
Allyx Therapeutics Inc.
Allyx Therapeutics Announces Positive Phase 1b Multiple Ascending Dose Data and Advances ALX-001 to Patients
RaceTrac’s Run For Research 5K Returns to Truist Park September 16
03. August 2023 14:00 ET
|
Racetrac, Inc.
ATLANTA, GA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- According to The Michael J. Fox Foundation for Parkinson’s Research (MJFF), six million people worldwide live with Parkinson’s disease. One million of...
Amydis Awarded Third Grant From The Michael J. Fox Foundation To Support First-In-Human Study of a Retinal Tracer for Parkinson’s Disease
27. Oktober 2022 07:00 ET
|
Amydis, Inc.
SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Amydis Inc., a privately held clinical-stage company pioneering a platform of diagnostic drug candidates targeting molecular biomarkers in the eye, today...
Amydis Announces Successful Completion of Pre-IND Meeting with the FDA for the Development of a First-in-Class Retinal Tracer for the Diagnosis of Alpha-synucleinopathies
26. April 2021 07:00 ET
|
Amydis, Inc.
SAN DIEGO, April 26, 2021 (GLOBE NEWSWIRE) -- Amydis Inc., a leading ocular tracer biotechnology company with a broad portfolio of diagnostic candidates for detection of neurodegenerative diseases...
Amydis Receives Parkinson’s Disease Grant from Michael J. Fox Foundation
10. Juli 2018 07:00 ET
|
Amydis, Inc.
SAN DIEGO, July 10, 2018 (GLOBE NEWSWIRE) -- Amydis, Inc., a privately-held pharmaceutical company developing proprietary chemistry and innovative approaches for the detection of amyloid-related...
Taconic Biosciences Announces Release of New Parkinson’s Disease Animal Model
25. April 2017 12:54 ET
|
Taconic Biosciences
HUDSON, N.Y., April 25, 2017 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in genetically engineered mouse models and associated services, announced that effective April 17, 2017, in...
DiamiR Announces Grant From The Michael J. Fox Foundation for Parkinson's Research to Advance Assessment of Brain-Enriched microRNA Biomarkers in Plasma
14. Juli 2014 11:00 ET
|
DiamiR LLC
MONMOUTH JUNCTION, NJ--(Marketwired - July 14, 2014) - DiamiR, LLC, a molecular diagnostics company focused on the development and commercialization of innovative tests for detection and monitoring...
MIT Enterprise Forum of Cambridge Presents Session on Neuroscience, Featuring Keynote by Dr. Darryle Schoepp, Renowned Drug Discovery Scientist at Merck
30. Oktober 2008 09:14 ET
|
MIT Enterprise Forum of Cambridge
CAMBRIDGE, MA--(Marketwire - October 30, 2008) - On November 12, the MIT Enterprise Forum of
Cambridge, in collaboration with the McGovern Institute for Brain
Research at MIT, will feature a keynote...